Summary
Grifols SA (Grifols) is a pharmaceutical and chemical company focused at improving the health and well being of people around the world. It carries out the research, development, manufacturing and marketing of plasma-derived therapies, diagnostic products and hospital pharmacy products. It produces plasma derived protein therapies for patients suffering with rare, genetic diseases and life-threatening infections. Grifols has plasma donation centers across the US and industrial facilities in Australia, Mexico, Switzerland, the US and Spain. It established a system that carries out operations from collecting source plasma to the fractionation, purification and production of the finished product. Grifols is headquartered in Sant Cugat del Valles, Barcelona, Spain.
Grifols SA (GRF) - Medical Equipment - Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Medical eTrack deals database, and primary and secondary research.
Scope
- Financial Deals - Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals - Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description - A brief description of the company's operations.
- Key Employees - A list of the key executives of the company.
- Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors - A list of the key competitors of the company.
- Key Recent Developments - A brief on recent news about the company.
Reasons to Buy
Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company's business segments' expansion / divestiture strategy
- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.
Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.
Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
'
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 5
Grifols SA, Medical Equipment, Deals By Year, 2011 to YTD 2017 6
Grifols SA, Medical Equipment Deals By Type, 2011 to YTD 2017 7
Grifols SA, Medical Equipment, Deals By Region, 2011 to YTD 2017 8
Grifols SA, Medical Equipment, Deals By Market, 2011 to YTD 2017 9
Grifols SA, Medical Equipment, Deals Summary, 2011 to YTD 2017 10
Grifols SA, Medical Equipment, Deal Details 11
Asset Purchase 11
Grifols Acquires Nucleic Acid Testing Donor Screening Unit from Hologic for USD1.85 Billion 11
Grifols Acquires Blood Transfusion Diagnostics Business from Novartis for USD1.66 Billion 12
Partnerships 13
Singulex Enters into Licensing Agreement with Grifols 13
Grifols Enters Into Distribution Agreement With Kainos Labs 14
Health Robotics Enters Into Co-Marketing Agreement With Grifols 15
Grifols Enters Into Co-Marketing Agreement With Novartis 15
Equity Offering 16
Grifols Invests USD50 Million in Singulex 16
TiGenix Completes Private Placement Of Shares For US$16.2 Million 17
Debt Offering 18
Grifols Completes Public Offering Of Bonds Due 2022 For US$1 Billion 18
Acquisition 19
Grifols Acquires Additional 32.93% Stake in Progenika Biopharma for USD27 Million 19
Grifols Acquires 50% Stake in Kiro Robotics for USD27 Million 20
Alken Asset Management Sells 2.72% Stake In Grifols For US$227 Million 20
Grifols Completes Acquisition Of 35% Stake In Aradigm For US$26 Million 21
Grifols Acquires 60% Stake In Progenika Biopharma For US$48 Million 22
Grifols Acquires Remaining 51% Stake In Lateral-Medion 23
Grifols SA - Key Competitors 25
Key Employees 26
Locations And Subsidiaries 27
Head Office 27
Other Locations & Subsidiaries 27
Recent Developments 32
Financial Announcements 32
Feb 28, 2017: Grifols' revenues exceed Euros 4,000 million, driven by +6.5% growth of the Bioscience Division 32
Nov 08, 2016: Sales of the Bioscience Division grow by +6.5%, increasing Grifols' revenues to EUR 2,952 million 40
Jul 28, 2016: Sales of the Bioscience Division grow by +7.0%, increasing Grifols' revenues by +2.7% to EUR 1,952 million 44
May 05, 2016: Grifols' revenues increase by +5.6% to Euros 959 million, driven by growth of +10.9% for the Bioscience Division 50
Feb 29, 2016: Grifols' revenues grow by 17.3% to Euros 3,935 million, and net profit grows by 13.2% reaching Euros 532 million 54
Other Significant Developments 61
Oct 20, 2016: The CLIA Lab at the Grifols Immunohematology Center Will Now Offer Both Serology and Molecular Tests 61
Jul 05, 2016: Pedigri: the tool that increases the information transparency to the plasma-derived manufactured in Clayton 62
Jun 16, 2016: Grifols confirms that it has voluntarily signed the EFPIA Code of Conduct 63
Mar 03, 2016: Grifols: The company doesn´t have any tax litigation in any country where it operates 64
Appendix 65
Methodology 65
About GlobalData 65
Contact Us 65
Disclaimer 65
List of Tables
Grifols SA, Medical Equipment, Key Facts, 2016 1
Grifols SA, Medical Equipment, Deals Summary, 2011 to YTD 2017 1
Grifols SA, Medical Equipment, Deals By Year, 2011 to YTD 2017 6
Grifols SA, Medical Equipment Deals By Type, 2011 to YTD 2017 7
Grifols SA, Medical Equipment, Deals By Region, 2011 to YTD 2017 8
Grifols SA, Deals By Market, 2011 to YTD 2017 9
Grifols SA, Medical Equipment, Deals Summary, 2011 to YTD 2017 10
Grifols Acquires Nucleic Acid Testing Donor Screening Unit from Hologic for USD1.85 Billion 11
Grifols Acquires Blood Transfusion Diagnostics Business from Novartis for USD1.66 Billion 12
Singulex Enters into Licensing Agreement with Grifols 13
Grifols Enters Into Distribution Agreement With Kainos Labs 14
Health Robotics Enters Into Co-Marketing Agreement With Grifols 15
Grifols Enters Into Co-Marketing Agreement With Novartis 15
Grifols Invests USD50 Million in Singulex 16
TiGenix Completes Private Placement Of Shares For US$16.2 Million 17
Grifols Completes Public Offering Of Bonds Due 2022 For US$1 Billion 18
Grifols Acquires Additional 32.93% Stake in Progenika Biopharma for USD27 Million 19
Grifols Acquires 50% Stake in Kiro Robotics for USD27 Million 20
Alken Asset Management Sells 2.72% Stake In Grifols For US$227 Million 20
Grifols Completes Acquisition Of 35% Stake In Aradigm For US$26 Million 21
Grifols Acquires 60% Stake In Progenika Biopharma For US$48 Million 22
Grifols Acquires Remaining 51% Stake In Lateral-Medion 23
Grifols SA, Key Competitors 25
Grifols SA, Key Employees 26
Grifols SA, Other Locations 27
Grifols SA, Subsidiaries 27
List of Figures
Grifols SA, Medical Equipment, Deals by Type, 2011 to YTD 2017 1
Grifols SA, Medical Equipment, Deals By Year, 2011 to YTD 2017 1
Grifols SA, Medical Equipment, Deals By Region, 2011 to YTD 2017 1
Grifols SA, Medical Equipment, Deals By Market, 2011 to YTD 2017 1
Grifols SA, Medical Equipment, Deals By Year, 2011 to YTD 2017 6
Grifols SA, Medical Equipment, Deals by Type, 2011 to YTD 2017 7
Grifols SA, Medical Equipment, Deals By Region, 2011 to YTD 2017 8
Grifols SA, Medical Equipment, Deals by Market, 2011 to YTD 2017 9
